0
2021
Ophthalmic Drugs Market

Ophthalmic Drugs Market

by Indication (Dry Eye, Glaucoma, Infection/Inflammation/Allergy, Retinal Disorders, and Others), Type (Prescription Drugs and Over-the-counter-Drugs), Dosage Form (Liquid Ophthalmic Drug Forms, Solid Ophthalmic Drug Forms, Semi-Solid Ophthalmic Drug Forms, Multicompartment Drug Delivery Systems, and Other Ophthalmic Drug Forms), Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies and Others), and Therapeutic Class (Anti-Glaucoma, Anti-infection, Anti-inflammation, Anti-allergy, and Others): Global Opportunity Analysis and Industry Forecast, 2020-2027
Update Available On-Demand

Report Code: A00220
Pages: 564
Apr 2021 | 27702 Views
Author(s) : Kishor S , Linu D
Tables: 319
Charts: 64
  • Formats*:

  • Single User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Ophthalmic Drugs Market

Request Now !

Ophthalmic Drugs Market Overview:

The global ophthalmic drugs market generated $36,488.48 million in 2019, and is projected to reach $58,134.92 million by 2027, growing at a CAGR of 5.6% from 2020 to 2027. The ophthalmic drugs are the formulations that are designed for the treatment of eye diseases such as cataract, glaucoma, color blindness, diabetic macular edema, cytomegalovirus (CMV) retinitis, and age-related macular degeneration (AMD).

Increase in geriatric population; rise in prevalence of eye disease such as glaucoma, cataract and macular degeneration; surge in demand of ophthalmic drug, and increase in investment in R&D activities by various healthcare companies are the key factors that drive the growth of the global ophthalmic drugs market. In addition, surge in demand for ophthalmic drugs, rise in awareness about healthcare to prevent the risk of eye diseases, and initiatives taken by government for development & manufacturing of different combination of ophthalmic drugs propel the growth of the market. However, prolonged time period for manufacturing and formulating the ophthalmic drug as well as side effects associated with the ophthalmic drugs are expected to restrict the market growth during the forecast period.

Ophthalmic-Drugs-Market

Ophthalmic Drugs Market Segmentation

The ophthalmic drugs market is segmented into indication, type, dosage form, distribution channel, therapeutic class, and region. By indication, the market is divided into dry eye, glaucoma, infection/inflammation/allergy, retinal disorders, and others. The retinal disorders segment is further classified into wet age-related macular degeneration, dry age-related macular degeneration, diabetic retinopathy, and others. On the basis of type, the market is fragmented into prescription drugs and over-the-counter drugs. Depending on dosage form, it is segregated into liquid ophthalmic drug forms, solid ophthalmic drug forms, semisolid ophthalmic drug forms, multicompartment drug delivery systems, and other ophthalmic drug forms. By distribution channel, the ophthalmic drugs market is differentiated into hospital pharmacies, drug stores, online pharmacies, others. The therapeutic class covered in the study include anti-glaucoma, anti-infection, anti-inflammation, anti-allergy and others.

Ophthalmic Drugs Market
By Indication

Your browser does not support the canvas element.

Retinal disorder Platforms segment held a dominant position in 2019 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Region wise, the ophthalmic drugs market is analyzed across North America (the U.S., and rest of North America), Europe (Germany, the UK, France, Spain, Italy, Poland, and rest of Europe), Asia-Pacific (Malaysia, Vietnam, Thailand, Philippines, and rest of Asia-Pacific), Middle East (UAE, Saudi Arabia, Palestine, Jordan, Bahrain, Qatar, Azerbaijan, Georgia, Iraq, Pakistan, Kuwait, Israel, Kazakhstan, Uzbekistan, Tajikistan, Kyrgyzstan, Turkmenistan, Rest of Middle East), North Africa (Egypt, Morocco, Tunisia, Algeria, Lybia, and rest of North Africa) and rest of world (Brazil and others).

Ophthalmic Drugs Market
By Region

2027
North America 
Europe
Asia-pacific
Middle East
North Africa
Rest Of World

North America was holding a dominant position in 2019 and would continue to maintain the lead over the analysis period.

Get more information on this report : Request Sample Pages

Segment review

Depending on type of indication, the retinal disease segment dominated the global ophthalmic drugs market in 2019, and is anticipated to continue this trend during the forecast period, due to increase in geriatric population, rise in prevalence of macular degeneration, and surge in the sale of ophthalmic drug for the treatment of retinal disease. However, the glaucoma segment is expected to witness considerable growth during the forecast period due to rise in the prevalence of glaucoma, increase in the need for ophthalmic drug, and surge in awareness about the prevention and treatment of glaucoma. 

On the basis of the type of therapeutic class, the anti-inflammatory segment exhibited the highest growth in 2019, and is anticipated to lead in the near future due to increase in prevalence of allergic conjunctivitis and hypersensitivity reactions and increase in demand of anti-inflammatory drug in wide range of condition such as uveitis, cystoid macular edema, and scleritis. However, the anti-allergy segment is expected to witness considerable growth during the forecast period, due to increase in prevalence of allergic conjunctivitis. 

North America accounted for a major share in the ophthalmic drugs market in 2019, and is expected to maintain its dominance during the forecast period, owing to rise in prevalence of the geriatric population, increase in prevalence of eye disease, and initiatives taken by government for eye health. Furthermore, rise in awareness about the prevention and treatment of eye disease, and increase in demand for advanced healthcare facilities are contributing toward the growth of the market. Moreover, upsurge in R&D activities in healthcare sector to develop novel ophthalmic drugs and presence of major players operating in the region fuel the growth of the market. However, Asia-Pacific is expected to register highest CAGR of 7.1% from 2020 to 2027, owing to increase in prevalence glaucoma and rise in awareness regarding ophthalmic drugs. 

The key players operating in the global ophthalmic drugs market include AbbVie Inc. (Allergen plc.), Alcon Inc., Bausch & Lomb Incorporated, F. Hoffmann-La Roche Ltd (Genentech, Inc.), Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. (Actavis Generics).

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the ophthalmic drugs market, and the current trends and future estimations to elucidate the imminent investment pockets
  • It presents a quantitative analysis of the market from 2019 to 2027 to enable stakeholders to capitalize on the prevailing ophthalmic drugs market opportunities
  • Extensive analysis of the market based on procedures and services assists to understand the trends in the industry
  • Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the ophthalmic drugs market

Ophthalmic Drugs Market Report Highlights

Aspects Details
BY INDICATION
  • Dry Eye
  • Glaucoma
  • Infection/Inflammation/Allergy
  • Retinal Disorders
    • Wet Age-related Macular Degeneration
    • Dry Age-related Macular Degeneration
    • Diabetic Retinopathy
    • Others
  • Others
BY TYPE
  • Prescription Drugs
  • Over-the-counter Drugs
BY DOSAGE FORM
  • Liquid Ophthalmic Drug Forms
  • Solid Ophthalmic Drug Forms
  • Semisolid Ophthalmic Drug Forms
  • Multicompartment Drug Delivery Systems
  • Other Ophthalmic Drug Forms
BY DISTRIBUTION CHANNEL
  • Hospital Pharmacies
  • Drug Stores
  • Online Pharmacies
  • Others
BY THERAPEUTIC CLASS
  • Anti-glaucoma
  • Anti-infection
  • Anti-inflammation
  • Anti-allergy
  • Others
BY REGION
  • North America  (U.S., Rest of North America)
  • Europe  (Germany, France, UK, Italy, Spain, Poland, Rest of Europe)
  • Asia-Pacific  (Malaysia, Vietnam, Thailand, Philippines, Rest of Asia-Pacific)
  • Middle East  (UAE, South Arabia, Palestine, Jordan, Bahrain, Qatar, Azerbaijan, Georgia, Iraq, Pakistan, Kuwait, Israel, Kazakhstan, Uzbekistan, Tajikistan, Kyrgyzstan, Turkmenistan, Rest of Middle East)
  • North Africa  (Egypt, Morocco, Tunisia, Algeria, Lybia, Rest of North Africa)
  • Rest of World  (Brazil, Others)
Key Market Players ABBVIE Inc. (ALLERGAN PLC), Alcon, Inc., BAUSCH & LOMB INCORPORATED, F. HOFFMANN-LA ROCHE LTD (GENENTECH, INC.), .NOVARTIS AG, PFIZER INC., REGENERON PHARMACEUTICALS INC., SANTEN PHARMACEUTICAL CO., LTD, SUN PHARMACEUTICAL INDUSTRIES LIMITED, TEVA PHARMACEUTICAL INDUSTRIES LTD. (ACTAVIS GENERICS)
 

Loading Table Of Content...


 
 


The ophthalmic drugs market is expected to exhibit considerable growth potential in the near future. This is attributed to factors such as technological advancements in research and development for ophthalmic drugs; rise in prevalence of eye diseases such as glaucoma, dry eye, cataract, and macular degeneration; increase in geriatric population; and surge in awareness among consumers regarding healthcare sectors. Moreover, the ophthalmic drugs market has gained high traction in the healthcare industry over years, as these drugs are intended for treatment or management of eye disease.

As per the analysis in the report, the market in North America is projected to register highest growth rate, due to the presence of large population base coupled with a rise in prevalence of eye diseases, increase in awareness about prevention, treatment of ophthalmic disorder, and a rise in the geriatric population. 

In addition, the risk of side effects associated with ophthalmic drugs such as orbital inflammation and loss of calcium in bone and prolonged timelines for the development of efficient ophthalmic formulations are anticipated to restrain the market growth during the forecast period.
 

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The key trends in the Ophthalmic Drugs Market are increase in prevelence of opthalmic disorder and advancemenmt in technology for healthcare sector.

A. No, there is no value chain analysis provided in the Ophthalmic Drugs Market report

A. Yes, Ophthalmic Drugs companies are profiled in the report

A. The market value of Ophthalmic Drugs Market in 2020 was $39,590 Million

A. The forecast period in the report is from 2020 to 2027

A. The top companies that hold the market share in Ophthalmic Drugs Market are AbbVie Inc., Alcon, Inc., Bausch & Lomb Inc., F.Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd.

A. The total market value of Ophthalmic Drugs Market is $36,488.48 million in 2019

A. The base year for the report is 2019

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Free Sample
RELATED TAGS

Purchase Full Report of
Ophthalmic Drugs Market

Start reading instantly.
This Report and over 19,272+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $4,065
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Apr 2022 - Apr 2023)
  • Data Pack
  • $4,650
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Apr 2022 - Apr 2023)
  • Single User
  • $6,180
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Apr 2022 - Apr 2023)
  • Five Users
  • $6,900
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Apr 2022 - Apr 2023)
  • Enterprise
    License/PDF

  • $10,860
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Apr 2022 - Apr 2023)
  • Library
    Membership

  • $ 999
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers